PMID- 21820917
OWN - NLM
STAT- MEDLINE
DCOM- 20120302
LR  - 20240417
IS  - 1096-3618 (Electronic)
IS  - 1044-5323 (Print)
IS  - 1044-5323 (Linking)
VI  - 23
IP  - 6
DP  - 2011 Dec
TI  - Clinical perspectives for regulatory T cells in transplantation tolerance.
PG  - 462-8
LID - 10.1016/j.smim.2011.07.008 [doi]
AB  - Three main types of CD4+ regulatory T cells can be distinguished based upon 
      whether they express Foxp3 and differentiate naturally in the thymus (natural 
      Tregs) or are induced in the periphery (inducible Tregs); or whether they are 
      FoxP3 negative but secrete IL-10 in response to antigen (Tregulatory type 1, Tr1 
      cells). Adoptive transfer of each cell type has proven highly effective in mouse 
      models at preventing graft vs. host disease (GVHD) and autoimmunity. Although 
      clinical application was initially hampered by low Treg frequency and unfavorable 
      ex vivo expansion properties, several phase I trials are now being conducted to 
      assess their effect on GVHD following hematopoietic stem cell transplantation 
      (HSCT) and in type I diabetes. Human Treg trials for HSCT recipients have 
      preceded other indications because GVHD onset is precisely known, the time period 
      needed for prevention relatively short, initial efficacy is likely to provide 
      life-long protection, and complications of GVHD can be lethal. This review will 
      summarize the clinical trials conducted to date that have employed Tregs to 
      prevent GVHD following HSCT and discuss recent advances in Treg cellular therapy.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Hippen, Keli L
AU  - Hippen KL
AD  - University of Minnesota Cancer Center, Division of Bone Marrow Transplantation, 
      Minneapolis, MN, USA. hippe002@umn.edu
FAU - Riley, James L
AU  - Riley JL
FAU - June, Carl H
AU  - June CH
FAU - Blazar, Bruce R
AU  - Blazar BR
LA  - eng
GR  - P01 AI056299-07/AI/NIAID NIH HHS/United States
GR  - R01 CA72669/CA/NCI NIH HHS/United States
GR  - R01 CA072669/CA/NCI NIH HHS/United States
GR  - P01 CA142106/CA/NCI NIH HHS/United States
GR  - HL56067/HL/NHLBI NIH HHS/United States
GR  - R01 CA072669-14/CA/NCI NIH HHS/United States
GR  - P01 AI056299/AI/NIAID NIH HHS/United States
GR  - R01 AI034495-18/AI/NIAID NIH HHS/United States
GR  - F32 CA067493-01/CA/NCI NIH HHS/United States
GR  - P01 CA142106-08/CA/NCI NIH HHS/United States
GR  - CA067493/CA/NCI NIH HHS/United States
GR  - AI34495/AI/NIAID NIH HHS/United States
GR  - R01 AI034495/AI/NIAID NIH HHS/United States
GR  - R01 HL056067-17/HL/NHLBI NIH HHS/United States
GR  - R01 HL056067/HL/NHLBI NIH HHS/United States
GR  - AI056299/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110805
PL  - England
TA  - Semin Immunol
JT  - Seminars in immunology
JID - 9009458
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Graft vs Host Disease/immunology
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - *Transplantation Tolerance
PMC - PMC3230779
MID - NIHMS316601
EDAT- 2011/08/09 06:00
MHDA- 2012/03/03 06:00
PMCR- 2012/12/01
CRDT- 2011/08/09 06:00
PHST- 2011/06/21 00:00 [received]
PHST- 2011/07/15 00:00 [accepted]
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2012/03/03 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - S1044-5323(11)00064-9 [pii]
AID - 10.1016/j.smim.2011.07.008 [doi]
PST - ppublish
SO  - Semin Immunol. 2011 Dec;23(6):462-8. doi: 10.1016/j.smim.2011.07.008. Epub 2011 
      Aug 5.